Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Coral Reefer is a brand of cannabis-based medicinal and recreational products developed through a partnership between Jimmy Buffett's Margaritaville Enterprises and Surterra Wellness (now Parallel). The product line features various ratios of tetrahydrocannabinol (THC) and cannabidiol (CBD) designed to provide specific therapeutic effects, categorized by names such as "Low Tide" (high CBD) and "High Tide" (high THC). These products are primarily indicated for symptom management in conditions such as chronic pain, anxiety, and insomnia, leveraging the effects of cannabinoids on the endocannabinoid system. The mechanism of action involves the activation of CB1 and CB2 receptors by THC to produce analgesic and psychoactive effects, while CBD acts as a negative allosteric modulator of CB1 and interacts with various non-cannabinoid targets like 5-HT1A receptors to provide anxiolytic and anti-inflammatory benefits.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Coral Reefer.